Monday, 30 January 2012

2009 - Aspirin & NSAID for cancer prevention: an international consensus statement

reposted from:
crabsallover highlightskey pointscomments / links.

The Lancet Oncology, Volume 10, Issue 5, Pages 501 - 507, May 2009
doi:10.1016/S1470-2045(09)70035-XCite or Link Using DOI

Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement

Prof Jack Cuzick PhD a Corresponding AuthorEmail AddressFlorian Otto MD b cProf John A Baron MD dProf Powel H Brown MD eProf John Burn PhD f,Peter Greenwald MD gProf Janusz Jankowski MD h iProf Carlo La Vecchia MD jProf Frank Meyskens MD kHans Jörg Senn MDb cProf Michael Thun MD l


Evidence clearly shows a chemopreventive effect for aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) on colorectal cancer and probably other cancer types; however, data on the risk—benefit profile for cancer prevention are insufficient and no definitive recommendations can be made. Aspirin has emerged as the most likely NSAID for use in chemoprevention because of its known cardiovascular benefit and available safety and efficacy data. Other traditional NSAIDs, particularly sulindac, and selective COX-2 inhibitors are now given to patients at high risk of colorectal cancer, although these drugs do not provide cardioprotection. More studies of aspirin and cancer prevention are needed to define the lowest effective dose, the age at which to initiate therapy, the optimum treatment duration, and the subpopulations for which the benefits of chemoprevention outweigh the risks of adverse side-effects. Although it might be possible to answer some of these questions with longer follow-up of existing clinical trials, randomised controlled trials with new study designs will be needed. Future projects should investigate the effects of aspirin treatment on multiple organ systems. Cancers of interest are colorectal, breast, prostate, lung, stomach, and oesophageal. The main side-effect of aspirin is peptic ulcers; therefore coadministration of aspirin with a proton-pump inhibitor is an attractive option and is under investigation in the AspECT trial.
a Cancer Research UK Centre for Epidemiology, Mathematics, and Statistics, Queen Mary University of London, London UK
b Tumor Center ZeTuP, St Gallen, Switzerland
c Department of Hematology and Oncology, University Medical Center, Freiburg, Germany
d Dartmouth Medical School, Hanover, NH, USA
e Baylor College of Medicine, Houston, TX, USA
f Newcastle University, Institute for Human Genetics, Newcastle upon Tyne, UK
g Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
h University of Oxford, Oxford, UK
i Institute for Cellular and Molecular Sciences, Queen Mary's College, University of London, London UK
j Mario Negri Institute for Pharmacological Research and University of Milan, Milan, Italy
k Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Irvine, Orange, CA, USA
l Epidemiology and Surveillance Research, American Cancer Society, Atlanta, GA, USA
Corresponding Author Information Correspondence to: Prof Jack Cuzick, Cancer Research UK Centre for Epidemiology, Mathematics, and Statistics, Queen Mary University of London, Barts & The London School of Medicine and Dentistry, Wolfson Institute of Preventive Medicine, Charterhouse Square, London EC1M 6BQ, UK

No comments: